FDAnews Drug Daily Bulletin
Oct. 5, 2012 | Vol. 9 No. 196
Pharma Blog Watch
Former FDA Head Slams J&J Over Risperdal (Pharmalot blog)
Johnson & Johnson’s (J&J) latest setback in its seemingly futile attempts to defend its Risperdal marketing is trying to keep former FDA Commissioner David Kessler from testifying in a case involving a teenage boy who claims the drug caused him to grow breasts, blogger Ed Silverman writes. A scathing report Kessler wrote about J&J’s conduct might also have something to do with it, Silverman adds. “In his report, Kessler reviewed various efforts to promote Risperdal to physicians allegedly without providing sufficient side effect data.”
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.